Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis.

PLR accounted for nearly 40% of the TNFi failures in axial SpA patients. Older age, negative HLA-B27, higher baseline disease activity, and treatment with soluble TNF receptors were the independent predictors of the primary nonresponse to TNFi.